logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > Pharmaceutical Intermediates > Tofacitinib Citrate CAS 540737-29-9 Pharmaceutical Intermediates

Tofacitinib Citrate CAS 540737-29-9 Pharmaceutical Intermediates

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 540737-29-9

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Aluminum Foil Bag, Drum

Delivery Time: 7-15DAY

Payment Terms: D/A,L/C,D/P,T/T,Western Union,MoneyGram

Supply Ability: G,KG,TON

Get Best Price
Highlight:

Tofacitinib Citrate

,

CAS 540737-29-9 Tofacitinib Citrate

Appearance::
White To Beige Powder
CAS NO::
540737-29-9
Molecular Formula::
C22H28N6O8
Molecular Weight::
504.49300
EINECS NO::
638-826-4
MDL NO::
MFCD23703608
Appearance::
White To Beige Powder
CAS NO::
540737-29-9
Molecular Formula::
C22H28N6O8
Molecular Weight::
504.49300
EINECS NO::
638-826-4
MDL NO::
MFCD23703608
Tofacitinib Citrate CAS 540737-29-9 Pharmaceutical Intermediates

Product Description:

Product Name: Tofacitinib citrate CAS NO: 540737-29-9      

                    

Synonyms:

3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate;

Tofacitinibcitrate;

2-hydroxypropane-1,2,3-tricarboxylic acid,3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile;

 

Chemical & Physical Properties:

Appearance: White to beige powder       

Assay :≥99.0%

Melting Point: 201℃ (decomp)

Storage Temp.: Room temp

Solubility: DMSO: soluble5mg/mL (clear solution; warmed)


Safety Information:

WGK Germany: 3

HS Code: 29335990


CP-690550 is a pyrrolo[2,3-d]pyrimidine derivative, as Janus kinase inhibitor for treatment of rheumatoid arthritis. Torfacitinib citrate may be used in combination with methotrexate for the treatment of active rheumatoid arthritis with inadequate response to tumor necrosis factor inhibitors. In clinical trials, the most common adverse reactions of tofacitinib citrate were upper respiratory tract infection, headache, diarrhea, nasal congestion, sore throat, and nasopharyngitis.


If you are interested in our products or have any questions, please feel free to contact us!


Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.